Ontology highlight
ABSTRACT:
SUBMITTER: Janne PA
PROVIDER: S-EPMC3048920 | biostudies-literature | 2011 Mar
REPOSITORIES: biostudies-literature
Jänne Pasi A PA Boss David S DS Camidge D Ross DR Britten Carolyn D CD Engelman Jeffrey A JA Garon Edward B EB Guo Feng F Wong Steven S Liang Jane J Letrent Stephen S Millham Robert R Taylor Ian I Eckhardt S Gail SG Schellens Jan H M JH
Clinical cancer research : an official journal of the American Association for Cancer Research 20110110 5
<h4>Purpose</h4>PF299804 is a potent, orally available, irreversible inhibitor of tyrosine kinase human epidermal growth factor receptors (HER) 1 (EGFR), HER2, and HER4. This first-in-human study investigated the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF299804 in patients with advanced solid malignancies.<h4>Experimental design</h4>PF299804 was administered once daily continuously (schedule A) and intermittently (schedule B). Dose escalation proceeded until intolerable t ...[more]